The most significant recent development for SpringWorks is the agreement by Merck (NSE:PROR) KGaA to acquire the company for $47 per share, representing a total equity value of approximately $3.9 ...

Merck KGaA has reached an agreement with SpringWorks on a $47-per-share takeover deal that values the US biotech at $3.9 billion. The acquisition – which was confirmed to be in the final stages ...

Reacting to press speculation, Merck KGaA has acknowledged that talks to buy US biotech SpringWorks are now in the late stages and are revolving around an offer of around $47 per share.

Year to date, shares of SpringWorks have risen 28.6% against the industry’s decline of 5.5%. In April 2025, Merck KGaA, Darmstadt, Germany, announced that it had agreed to acquire SpringWorks ...

In analyst updates, TD Cowen downgraded SpringWorks from Buy to Hold and adjusted the price target to $47.00, citing the proposed acquisition by Merck KGaA as a factor. Meanwhile, H.C. Wainwright ...

(Reuters) - Germany's Merck KGaA said on Thursday it is in late-stage talks to acquire U.S.-based SpringWorks Therapeutics for about $3.5 billion, a deal that could give it access to a recently ...

The German pharmaceutical company Merck KGaA is negotiating the acquisition of the American manufacturer of drugs for the treatment of cancer and rare diseases SpringWorks Therapeutics Inc. This is ...

SpringWorks Therapeutics brings to Merck KGaA two FDA-approved drugs, both currently under regulatory review in Europe. Beyond their initial applications in rare tumors, these small molecules are ...

Year to date, shares of SpringWorks have risen 28.6% against the industry’s decline of 5.5%. Image Source: Zacks Investment Research In April 2025, Merck KGaA, Darmstadt, Germany, announced that ...

During a live event, Hari Deshpande, MD, and participants discussed the DeFi trial and the management of nirogacestat in ...

SpringWorks Therapeutics, Inc. (NASDAQ: SWTX)’s sale to Merck KGaA, Darmstadt, Germany for $47.00 per share in cash. If you are a SpringWorks shareholder, click here to learn more about your ...